First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

Scientists have been studying other possible health benefits of GLP-1s. Popular obesity and diabetes drugs called GLP-1 ... use disorder," Dr. Maurice O'Farrell, lead author of the study and ...

People booze a lot less when taking GLP-1 drugs like Ozempic, a new study out of Ireland ... statistics show. Monkey Business – stock.adobe.com Harmful alcohol use accounts for about 2.6 million ...

Ozempic and similar drugs aren’t just for weight loss, more and more research is finding. New data is the latest to show that GLP-1 medications ... for alcohol use disorder, the study ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

The diabetes and weight loss drugs are “not cost-effective at their current prices, and are largely unavailable to people with lower incomes,” the report said.